A Radiocalibration Method with Pseudo Internal Standard to Estimate Circulating Metabolite Concentrations

• Baillie TA , CayenMN, FoudaHet al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188–196 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson S , KnadlerMP, Luffer-AtlasD. Overview of metabolite safety testing from an industry perspective. Bioanalysis. 2(7), 1249–1261 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson S , Luffer-AtlasD, KnadlerMP. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22, 243–256 (2009).
   PubMed Web of Science ®Google Scholar
• Baillie TA . Approaches to the safety assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem. Res. Toxicol. 22, 263–266 (2009).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22, 267–279 (2009).
   PubMed Web of Science ®Google Scholar
• Davis-Bruno KL , AtrakchiA. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res. Toxicol. 19, 1561–1563 (2006).
   PubMed Web of Science ®Google Scholar
• Humphreys WG , UngerSE. Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res. Toxicol. 19, 1564–1569 (2006).
   PubMed Web of Science ®Google Scholar
• Guengerich FP . Safety assessment of stable drug metabolites. Chem Res. Toxicol. 19, 1559–1560 (2006).
   Web of Science ®Google Scholar
• Smith DA , ObachRS. Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570–1579 (2006).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Williams DP, Park BK. Clearing the MIST of time: the impact of duration of administration on drug metabolite toxicity. Chem. Biol. Interact. 179, 60–67 (2009).
   PubMed Web of Science ®Google Scholar
• Atrakchi AH . Interpretation and considerations on the safety evaluation of human drug metabolites. Chem Res. Toxicol. 22, 1217–1220 (2009).
   PubMed Web of Science ®Google Scholar
• Pang KS . Safety testing of metabolites: expectations and outcomes. Chem. Biol. Interact. 179, 45–59 (2009).
   PubMed Web of Science ®Google Scholar
• Walker D , BradyJ, DalvieDet al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem. Res. Toxicol. 22, 1653–1662 (2009).
   PubMed Web of Science ®Google Scholar
• Frederick CB , ObachRS. Metabolites in safety testing: ‘MIST’ for the clinical pharmacologist. Clin. Pharmacol. Ther. 87, 345:350 (2010).
   PubMed Web of Science ®Google Scholar
• Luffer-Atlas D . Unique/major human metabolites: why, how, and when to test for safety in animals. Drug Metab. Rev. 40, 447–463 (2008).
   PubMed Web of Science ®Google Scholar
• Naito S , FurutaS, YoshidaTet al. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals. J. Toxicol. Sci. 32, 329–341 (2007).
   PubMedGoogle Scholar
• Robison TW , JacobsA. Metabolites in safety testing. Bioanalysis1(7), 1193–1200 (2009).
   PubMed Web of Science ®Google Scholar
• Leclercq L , CuyckensF, MannensGSJ, de Vries R, Timmerman P, Evans DC. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22, 280–293 (2009).
   PubMed Web of Science ®Google Scholar
• Srivastava A , Lian L-Y, Maggs JLet al. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab. Dispos. 38, 122–132 (2010).
   PubMed Web of Science ®Google Scholar
• Ellis MK , NaylorJL, GreenT, CollinsMA. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy. Drug Metab. Dispos. 23, 102–106 (1995).
   PubMed Web of Science ®Google Scholar
• Espina R , YuL, WangJet al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolite safety testing. Chem. Res. Toxicol. 22, 299–310 (2009).
   PubMed Web of Science ®Google Scholar
• Vishwanathan K , BabalolaK, WangJet al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22, 311–322 (2009).
   PubMed Web of Science ®Google Scholar
• Knapp DR . Handbook of Analytical Derivatization Reactions. Wiley Interscience, Somerset, NJ, USA (1979).
   Google Scholar
• Yu CP , ChenCL, GoryckiFL, NeissTG. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun. Mass Spectrom. 21, 497–502 (2007).
   PubMed Web of Science ®Google Scholar
• Sun P , WangX, AlquierL, MaryanoffCA. Determination of relative response factors of impurities in paclitaxel with high performance liquid chromatography equipped with ultraviolet and charged aerosol detectors. J. Chromatogr. A1177, 87–91 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA Guidance for industry: Safety testing of drug metabolites (2008) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf
   Google Scholar
• International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH M3 (R2): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (2009) www.ich.org/LOB/media/MEDIA5544.pdf
   Google Scholar
• US FDA Guidance for industry: Bioanalytical method validation (2001) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
   Google Scholar